MTOR and cancer: Although relatively few cancers harbor constitutively activating mutations in the mTOR gene or direct pathway regulators11,12, both mTOR complexes are essential effectors of the most common oncogenic drivers, including those in the Ras-driven MAPK and PI3K–AKT pathways7.